Neurocrine Biosciences Inc vs Tapestry, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Tapestry, Inc. trades at $140.62 (market cap $28.51B). The key difference: Tapestry, Inc. is the larger of the two by market cap, and Tapestry, Inc. pays a 1.13% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TPR | |
|---|---|---|
Market Cap | $17.40B | $28.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $160.49 |
52-Week Low | $123.10 | $95.69 |
Enterprise Value | $16.49B | $31.37B |
Dividend Yield | — | 1.13% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →